Oliver Reuss
Investment Manager at Boehringer Ingelheim Venture Fund GmbH
Germany
Overview
Work Experience
Executive Director / Investment Manager; Boehringer Ingelheim Venture Fund
2018 - Current
Head of Business Model & HealthCare Innovation
2014 - 2018
Head of Prescription Medicine Strategy & Strategic Intelligence
2013 - 2014
Senior Manager PM Strategy & Portfolio Management
2012 - 2013
International Business Analysis Manager
2008 - 2011
Member, Board of Directors
2025
C-mo is a wearable cough-monitoring device that provides a comprehensive assessment of cough’s distinctive characteristics. The information provided by C-mo will allow doctors to expand their knowledge base, possess a more comprehensive and objective information set and consequently, to provide more accurate diagnosis and prescribe more tailored treatments.
Member, Board of Directors
2024
Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.
Observer, Board of Directors
2024
Glox Therapeutics is developing precision, engineered protein bacteriocins to target drug-resistant pathogenic bacteria.
Member, Board of Directors
2021
Brainomix, Ltd. focuses on imaging software for neurological and cerebrovascular diseases and developed a software tool (e-ASPECTS) for the automated analysis of CT scans to detect early ischemic changes in the brain of patients with clinical signs of stroke. Currently, Brainomix utilizes its platform technology to expand into new therapeutic indications, including lung fibrosis and cancer. Brainomix is a spin-out from the University of Oxford, UK.
Member, Board of Directors
2020
Perfood develops digital therapeutics powered by proprietary technology for personalized stable-glycemic nutrition. Perfood is building a pipeline of therapeutic solutions, where its core competence of modulating the glucose metabolism and inflammatory processes add disease-specific value. Find out more on www.perfood.de
Member, Board of Directors
2019
Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. The goal is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Find out more on www.dopavision.com
Business Analyst
2007 - 2008
Postdoc
2006 - 2007